Biotechnology company 10x Genomics and Harvard University reached a Feb. 6 settlement in a patent lawsuit that they jointly ...

Barclays lowered the firm’s price target on 10x Genomics (TXG) to $15 from $18 and keeps an Overweight rating on the shares.Maximize Your ...

Genomics reported a Q4 EPS loss of $(0.40), missing estimates, while revenue declined 10% year over year. Analysts lowered ...

A Wednesday night earnings report left big questions about how the spending reductions would affect the company.

Q4 2024 Earnings Call Transcript February 12, 2025 10x Genomics, Inc. misses on earnings expectations. Reported EPS is $-0.4 EPS, expectations were $-0.29. Operator: Thank you for standing by. My name ...

Stifel lowered the firm’s price target on 10x Genomics (TXG) to $18 from $21 and keeps a Buy rating on the shares. The funding environment ...

CEO Serge Saxonov highlighted strong growth across platforms, with total revenue for Q4 2023 reaching $184 million, an 18% increase year-over-year. Spatial products contributed significantly, with ...

In this article, we are going to take a look at where 10x Genomics, Inc. (NASDAQ:TXG) stands against the other stocks in Cathie Wood’s portfolio. Cathie Wood is one of Wall Street’s most ...

CZI is embarking on this landmark initiative in collaboration with partners 10x Genomics, Ultima Genomics, and a group of leading researchers. Industry partners are enabling data generation at ...

CZI is embarking on this landmark initiative in collaboration with partners 10x Genomics, Ultima Genomics, and a group of leading researchers. Industry partners are enabling data generation at ...

The market expects 10x Genomics (TXG) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...